Phase 3Completed
China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2)
- Sponsor
- Tulane University (Academic or other)
- Enrolment
- 4,810 enrolled
- Conditions
- Acute Ischemic Stroke
- Interventions
- Early antihypertensive treatment; Delayed antihypertensive treatment
- Ages
- adults, older adults
- Registry
- NCT03479554
From the registry
The investigators propose to conduct a multicenter randomized trial to test the primary hypothesis of whether early antihypertensive treatment starting between the first 24-48 hours after the onset of an acute ischemic stroke will reduce the risk of composite case-fatality and major disability (modified Rankin Scale score ≥3) at three months compared to delayed antihypertensive treatment (starting on day 8 after stroke onset). In the proposed China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2), the investigators will recruit 4,776 patients from 100 hospitals within the China-US Collaborative Stroke Clinical Trial Network. Eligibility criteria for the trial participants include age ≥40 years, acute ischemic stroke confirmed by CT/MRI, symptom onset between 24-48 hours, and average systolic blood pressure (BP) between 140-200 mmHg at randomization. Patients with extracranial or intracranial artery stenosis (≥70%) in both sides or the affected side, NIH Stroke Scale score of ≥21, Glasgow Coma Scale score \<8, preceding moderate or severe dependency (modified Rankin scale…
Primary outcomes
- Composite outcome of death and major disability